Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01276496
First received: January 12, 2011
Last updated: June 30, 2014
Last verified: March 2014
  Purpose

This phase I trial studies the side effects and the best dose of cilengitide when given together with paclitaxel in treating patients with advanced solid tumors that cannot be removed by surgery. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to the stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cilengitide together with paclitaxel may kill more tumor cells.


Condition Intervention Phase
Male Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Drug: cilengitide
Drug: paclitaxel
Other: laboratory biomarker analysis
Other: pharmacological study
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • MTD of cilengitide and paclitaxel, defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients as graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]
  • Number of all adverse events, graded according to the NCI CTCAE v4.0 [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    The number of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population.

  • Severity of all adverse events, graded according to NCI CTCAE v4.0 [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    The severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population.

  • Incidence of grade 3+ adverse events, as graded using NCI CTCAE v 4.0 [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    The number and severity of grade 3+ adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population.

  • Incidence of non-hematologic toxicity, evaluated via the ordinal Common Toxicity Criteria (CTC) [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

  • Incidence of hematologic toxicity, including thrombocytopenia, neutropenia, and leukopenia, evaluated via the ordinal CTC [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    Assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

  • Best response, defined to be complete response (CR) or partial response (PR) as assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: From start of the treatment until disease progression/recurrence, assessed up to 3 months ] [ Designated as safety issue: No ]
    Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by tumor group).

  • Time until any treatment related toxicity [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
  • Time until treatment related grade 3+ toxicity [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
  • Time until hematologic nadir for WBC [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
  • Time until hematologic nadir for ANC [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
  • Time until hematologic nadir for platelets [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
  • Time to treatment failure [ Time Frame: Time from registration to documentation of progression, unacceptable toxicity, or refusal to continue participation by the patient, assessed up to 3 months ] [ Designated as safety issue: No ]
  • Response rate, defined as the proportion of patients whose tumor responds to treatment (Cohort II) [ Time Frame: Up to 3 months ] [ Designated as safety issue: No ]
    Calculated as the number of eligible patients whose tumor meets the criteria for a CR or PR on two consecutive evaluations at least 6 weeks apart divided by the number of eligible patients with metastatic breast cancer refractory to taxanes who begin treatment. A 95% binomial confidence interval will be constructed for the true response rate.

  • Progression-free survival (PFS) (Cohort II) [ Time Frame: The time of registration to documentation of disease event where a disease event is local/regional/distant progression, contralateral breast disease, second primary disease or death due to any cause, assessed up to 3 months ] [ Designated as safety issue: No ]
    Kaplan-Meier method will be used to estimate the distribution of PFS time.

  • Overall survival (OS) (Cohort II) [ Time Frame: The time of registration to death due to any cause, assessed up to 3 months ] [ Designated as safety issue: No ]
    Kaplan-Meier method will be used to estimate the distribution of OS time.

  • Change in Cyr61 expression levels (Cohort II) [ Time Frame: Baseline to up to 3 months ] [ Designated as safety issue: No ]
    At the end of each cycle, the percent change in serum Cyr61 expression from pre-treatment levels will be determined for each patient. For each patient, a times series plot of the percent change in serum Cyr61 expression from pre-treatment levels will be constructed and visually inspected for trends across time as well as for differences between those who respond to treatment (CR or PR by RECIST criteria) and those who do not.

  • Change in Cyr61 expression levels (Cohort II) [ Time Frame: Baseline to 21 days ] [ Designated as safety issue: No ]
    A Wilcoxon rank sum test will be used to assess the percent change in Cyr61expression level after one cycle of treatment from pretreatment levels differs between those who progress within 120 days (within the first 6 cycles of treatment) and those who remain progression-free at least 120 days.


Secondary Outcome Measures:
  • Incidence of toxicity, as assessed using PRO-CTCAE [ Time Frame: Up to 3 months ] [ Designated as safety issue: Yes ]
    The PRO-CTCAE will be summarized descriptively, and the dropout rate will be used for feasibility study. Informal comparison and correlation of the PRO-CTCAE symptoms with their corresponding items in clinician reported CTCAE will be conducted in an exploratory manner. Chi-squared tests will be used without adjustment for multiple comparisons.


Other Outcome Measures:
  • Pharmacokinetic (PK) parameters of cilengitide, including area under curve (AUC), maximum concentration Cmax and trough plasma concentrations [ Time Frame: Baseline; 1, 1.5, 2, 3, 4, and 5 hours post-cilengitide day 1 of courses 1 and 2; 27 hours post-paclitaxel day 2 of courses 1 and 2 ] [ Designated as safety issue: No ]
    Analyses will be primarily descriptive in nature. PK parameters will be determined from the individual plasma concentration-time curves of cilengitide, using non-compartmental and/or compartmental models. These parameters will be correlated to clinical outcomes such as tumor response. The possible effects of cilengitide upon paclitaxel pharmacokinetics, and vice-versa, will be explored using standard parametric or non-parametric techniques.

  • PK parameters of paclitaxel, including AUC, Cmax and trough plasma concentrations [ Time Frame: Baseline; 1, 1.5, 2, 3, 4, and 5 hours post-cilengitide day 1 of courses 1 and 2; 27 hours post-paclitaxel day 2 of courses 1 and 2 ] [ Designated as safety issue: No ]
    Analyses will be primarily descriptive in nature. PK parameters will be determined from the individual plasma concentration-time curves of paclitaxel, using non-compartmental and/or compartmental models. These parameters will be correlated to clinical outcomes such as tumor response. The possible effects of cilengitide upon paclitaxel pharmacokinetics, and vice-versa, will be explored using standard parametric or non-parametric techniques.


Enrollment: 13
Study Start Date: December 2010
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (cilengitide, paclitaxel)

Patients receive cilengitide IV over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16.

Drug: cilengitide
Given IV
Other Name: EMD 121974
Drug: paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • TAX
  • Taxol
Other: laboratory biomarker analysis
Correlative studies
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the maximally tolerated dose (MTD) of cilengitide and paclitaxel at weekly dose schedule. (Cohort I) II. To describe the toxicities associated with cilengitide and paclitaxel. III. To describe any antitumor activity of cilengitide and paclitaxel at weekly dose schedule.

IV. To characterize pharmacokinetics (PK) of cilengitide and paclitaxel with the proposed schedule and correlate PK parameters to clinical outcome. (Cohort I) V. To examine the effect of cilengitide and paclitaxel on circulating cysteine-rich, angiogenic inducer, 61 (Cyr61) using a novel "sandwich enzyme-linked immunosorbent assay (ELISA)" and to correlate this effect with clinical response. (Cohort II) VI. To evaluate the information obtained through use of items from the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Phase I studies.

VII. To determine if tumor tissue expression of alpha v beta 3 (αvβ3) and CYR61 correlate with therapeutic response to cilengitide with paclitaxel. (Cohort II)

OUTLINE: This is a dose-escalation study of cilengitide.

Patients receive cilengitide intravenously (IV) over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16.

After completion of study treatment, patients are followed up for 3 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic proof of cancer that is now unresectable (solid tumors, excluding lymphoma)
  • For Cohort II only:

    • Histologic adenocarcinoma of the breast with manifestations of metastatic cancer or locally advanced, unresectable cancer
    • Estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptor negative disease per local standards
    • Refractory to taxanes which is defined as one of the following:
    • Having relapsed during or within 12 months of completing adjuvant paclitaxel or docetaxel
    • Disease progression while on any taxane in the locally advanced, unresectable or metastatic breast cancer setting
    • Ability and willingness to undergo biopsy for biomarker testing prior to start of treatment
    • Disease must be measurable by imaging-based evaluation per Response Evaluation Criteria in Solid Tumors (RECIST) criteria (v1.1)
    • Up to 5 prior regimens of chemotherapy for metastatic disease are allowed
  • Absolute neutrophil count (ANC) >= 1500/μL
  • Hemoglobin (Hgb) >= 9 g/dL
  • Platelets (PLT) >= 100,000/μL
  • Total bilirubin =< 1.5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) =< 3 x ULN or AST =< 5 x ULN if liver involvement
  • Creatinine =< 1.5 x ULN
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, or 1 (or KPS > 70)
  • Ability to provide informed consent
  • Willingness to return to the enrolling Mayo Clinic institution for follow-up
  • Life expectancy >= 12 weeks
  • All patients: Willingness to provide blood samples for the mandatory correlative research component
  • For Cohort II, tissue biopsies are mandatory
  • Women of childbearing potential only: Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential including women within 2 years of post-menopause

Exclusion Criteria:

  • Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Any of the following prior therapies:

    • Chemotherapy =< 21 days prior to registration
    • Mitomycin C/nitrosoureas =< 42 days prior to registration
    • Immunotherapy =< 14 days prior to registration
    • Biologic therapy =< 14 days prior to registration
    • Prior investigational therapy =< 28 days prior to registration
    • Full* field radiation therapy =< 28 days prior to registration or limited** field radiation therapy < 14 days prior to registration

      • Full field radiation encompasses the entire area of known disease involvement and surrounding uninvolved but at-risk areas, e.g. subtotal nodal (mantle and upper abdomen) or total nodal irradiation
      • Limited field radiation is restricted to treating only the known areas of clinical disease, e.g. involved-field therapy for lymphoma
    • Major surgery (i.e., laparotomy) =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; NOTE: Insertion of a vascular access device is not considered major or minor surgery in this regard
  • Unresolved toxicities from prior therapy with the exception of alopecia that have not resolved to =< grade 1, unless the patient has a chronic, stable =< grade 2 toxicity that would not interfere with the evaluation of the study agents
  • New York Heart Association classification III or IV
  • Central nervous system (CNS) metastases or seizure disorder; Note: CNS metastases are allowed if previously treated and stable for at least 4 weeks
  • Any of the following:

    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, injections, intrauterine device [IUD], or abstinence, etc.); oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study
    • NOTE: This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-FDA-approved indication and in the context of a research investigation)
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be HIV positive on HAART therapy as there is a risk for drug interaction with antiretroviral treatment
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
  • Other active malignancy =< 3 years prior to registration; EXCEPTIONS: Nonmelanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
  • History of myocardial infarction =< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
  • Uncontrolled hypertension, labile hypertension of history of poor compliance with antihypertensive medication
  • Patients with active, bleeding diathesis
  • Non-disease related- major surgery, =< 28 days or minor surgery =< 7 days prior to registration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01276496

Locations
United States, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224-9980
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Investigators
Principal Investigator: Julian Molina Mayo Clinic
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01276496     History of Changes
Obsolete Identifiers: NCT01647139
Other Study ID Numbers: NCI-2013-00619, NCI-2013-00619, U01CA069912, MC0915, 8335, U01CA069912, P30CA015083
Study First Received: January 12, 2011
Last Updated: June 30, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Breast Neoplasms, Male
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 21, 2014